Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes
Jennifer S. ten Kulve, Dick J. Veltman, Liselotte van Bloemendaal, et al.
Diabetes Care (2015) Vol. 39, Iss. 2, pp. 214-221
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1289
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, et al.
Nature Reviews Nephrology (2017) Vol. 13, Iss. 10, pp. 605-628
Closed Access | Times Cited: 310
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101882-101882
Open Access | Times Cited: 249
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi, Olivia M. Farr, Stergios A. Pοlyzos, et al.
Metabolism (2018) Vol. 92, pp. 170-192
Open Access | Times Cited: 228
GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
Olivia M. Farr, Michael Sofopoulos, Michael A. Tsoukas, et al.
Diabetologia (2016) Vol. 59, Iss. 5, pp. 954-965
Open Access | Times Cited: 213
Safety of Semaglutide
Mark M. Smits, Daniël H. van Raalte
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 173
Obesity: Current and potential pharmacotherapeutics and targets
Vidya Narayanaswami, Linda P. Dwoskin
Pharmacology & Therapeutics (2016) Vol. 170, pp. 116-147
Open Access | Times Cited: 171
Brain functional and structural magnetic resonance imaging of obesity and weight loss interventions
Guanya Li, Yang Hu, Wenchao Zhang, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 4, pp. 1466-1479
Open Access | Times Cited: 58
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Young Jin Tak, Sang Yeoup Lee
The World Journal of Men s Health (2020) Vol. 39, Iss. 2, pp. 208-208
Open Access | Times Cited: 128
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
Jang Won Son, Sungrae Kim
Diabetes & Metabolism Journal (2020) Vol. 44, Iss. 6, pp. 802-818
Open Access | Times Cited: 106
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non‐alcoholic fatty liver disease: A randomized trial
Wenhuan Feng, Yan Bi, Ping Li, et al.
Journal of Diabetes Investigation (2018) Vol. 10, Iss. 2, pp. 399-407
Open Access | Times Cited: 99
Paraventricular Thalamic Control of Food Intake and Reward: Role of Glucagon-Like Peptide-1 Receptor Signaling
Zhi Yi Ong, Jun Liu, Zhiping P. Pang, et al.
Neuropsychopharmacology (2017) Vol. 42, Iss. 12, pp. 2387-2397
Open Access | Times Cited: 93
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies
Zhou Zhang, Bing Zhang, Xin Wang, et al.
Diabetes Care (2019) Vol. 42, Iss. 7, pp. 1274-1283
Open Access | Times Cited: 87
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes
Valerie D Heuvelman, Daniël H. van Raalte, Mark M. Smits
Cardiovascular Research (2019) Vol. 116, Iss. 5, pp. 916-930
Open Access | Times Cited: 82
Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol
Candan Yasemin Eren, Arya Yigit, Ramazan Efe Dogruoz, et al.
Frontiers in Behavioral Neuroscience (2021) Vol. 14
Open Access | Times Cited: 71
Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review
Sebastian Badulescu, Aniqa Tabassum, Gia Han Le, et al.
Physiology & Behavior (2024) Vol. 283, pp. 114622-114622
Open Access | Times Cited: 8
Neural predictors of 12-month weight loss outcomes following bariatric surgery
Laura M. Holsen, Paul Davidson, Hilâl Cerit, et al.
International Journal of Obesity (2017) Vol. 42, Iss. 4, pp. 785-793
Open Access | Times Cited: 70
Neuromodulatory effects of anti-diabetes medications: A mechanistic review
Habib Yaribeygi, Milad Ashrafizadeh, Neil C. Henney, et al.
Pharmacological Research (2019) Vol. 152, pp. 104611-104611
Closed Access | Times Cited: 59
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Joanna Michałowska, Ewa Miller‐Kasprzak, Paweł Bogdański
Nutrients (2021) Vol. 13, Iss. 2, pp. 351-351
Open Access | Times Cited: 48
Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
Alessia Costa, Minrong Ai, Nicolas Nunn, et al.
Molecular Metabolism (2021) Vol. 55, pp. 101407-101407
Open Access | Times Cited: 48
Use of GLP‐1 receptor agonists and subsequent risk of alcohol‐related events. A nationwide register‐based cohort and self‐controlled case series study
Ida Kim Wium‐Andersen, Marie Kim Wium‐Andersen, Anders Fink‐Jensen, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 131, Iss. 5, pp. 372-379
Open Access | Times Cited: 32
Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice
Paola Pantanetti, Giovanni Cangelosi, Sara Alberti, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial
Lennart Tonneijck, Marcel H.A. Muskiet, Mark M. Smits, et al.
Diabetes Obesity and Metabolism (2017) Vol. 19, Iss. 12, pp. 1669-1680
Open Access | Times Cited: 59
Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption
Jennifer S. ten Kulve, Dick J. Veltman, Liselotte van Bloemendaal, et al.
Journal of Endocrinology (2016) Vol. 229, Iss. 1, pp. 1-12
Open Access | Times Cited: 56
Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues
Jennifer S. ten Kulve, Dick J. Veltman, Victor E. A. Gerdes, et al.
Diabetes Care (2017) Vol. 40, Iss. 11, pp. 1522-1529
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top